Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
1.60
0.00 (0.00%)
Real-time:   12:24PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.57 - 1.62
52 week 1.50 - 5.19
Open 1.58
Vol / Avg. 536,289.00/2.90M
Mkt cap 223.26M
P/E     -
Div/yield     -
EPS -0.66
Shares 139.54M
Beta 2.10
Inst. own 84%
Aug 5, 2014
Q2 2014 Zogenix Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 5, 2014
Q2 2014 Zogenix, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Jun 24, 2014
Zogenix Inc at JMP Securities Healthcare Conference
Jun 18, 2014
Zogenix Inc at Wells Fargo Healthcare Conference
Jun 4, 2014
Zogenix, Inc. at Jefferies Global Healthcare Conference - Webcast
May 21, 2014
Zogenix, Inc. Annual Shareholder Meeting
May 8, 2014
Q1 2014 Zogenix, Inc. Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 Zogenix, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -272.77% -244.93%
Operating margin -355.23% -161.13%
EBITD margin - -153.00%
Return on average assets -79.03% -83.71%
Return on average equity -805.55% -491.54%
Employees 114 -
CDP Score - -

Address

Suite 650, 12400 High Bluff Drive
SAN DIEGO, CA 92130
United States - Map
+1-858-2591165 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In April 2014, Endo International PLC acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Director
Age: 55
Bio & Compensation  - Reuters
Roger L. Hawley Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
R. Scott Shively Executive Vice President, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 49
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 51
Bio & Compensation  - Reuters